Hepatic sinusoidal obstruction syndrome/ veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea

키워드

참고문헌 (122)

1. McDonald GB, "Venocclusive disease of the liver after bone marrow transplantation : diagnosis, incidence, and predisposing factors", Hepatology, 4, pp.116~122 (1984)
2. McDonald GB, "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients", Ann Intern Med, 118, pp.255~267 (1993)
3. Jones RJ, "Venoocclusive disease of the liver following bone marrow transplantation", Transplantation, 44, pp.778~783 (1987)
4. Bearman SI, "The syndrome of hepatic veno-occlusive disease after marrow transplantation", Blood, 85, pp.3005~3020 (1995)
5. Coppell JA, "Hepatic veno-occlusive disease following stem cell transplantation : incidence, clinical course, and outcome", Biol Blood Marrow Transplant, 16, pp.157~168 (2010)
6. Mohty M, "Sinusoidal obstruction syndrome", veno-occlusive disease : current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation(EBMT), 2015, pp.50, 781~789
7. Mohty M, "Revised diagnosis and severity criteria for sinusoidal obstruction syndrome", veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation, 2016, pp.51, 906~912
8. Corbacioglu S, "Diagnosis and severity criteria for sinusoidal obstruction syndrome", veno-occlusive disease in pediatric patients : a new classification from the European society for blood and marrow transplantation, 2018, pp.53, 138~145
9. Marks DI, "Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia", Biol Blood Marrow Transplant, 25, pp.1720~1729 (2019)
10. Kantarjian HM, "Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia", N Engl J Med, 375, pp.740~753 (2016)
11. Khimani F, "Predictors of overall survival among patients treated with sirolimus", tacrolimus vs methotrexate, Bone Marrow Transplant, pp.2017, 52[DOI]
12. Bearman SI, "Venoocclusive disease of the liver : development of a model for predicting fatal outcome after marrow transplantation", J Clin Oncol, 11, pp.1729~1736 (1993)
13. Yoon JH, "Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation(EBMT)for sinusoidal obstruction syndrome", veno-occlusive disease(SOS, Bone Marrow Transplant, pp.2019, 54[DOI]
14. Richardson PG, "Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure", Blood, 127, pp.1656~1665 (2016)
15. Coppell JA, "Veno-occlusive disease : cytokines, genetics, and haemostasis", Blood Rev, 17, pp.63~70 (2003)
16. Carreras E, "The role of the endothelium in the short-term complications of hematopoietic SCT", Bone Marrow Transplant, 46, pp.1495~1502 (2011)
17. DeLeve LD, "Cellular target of cyclophosphamide toxicity in the murine liver : role of glutathione and site of metabolic activation", Hepatology, 24, pp.830~837 (1996)
18. Almog S, "Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination", Biol Blood Marrow Transplant, 17, pp.117~123 (2011)
19. Biedermann BC, "Vascular endothelium and graft-versushost disease", Best Pract Res Clin Haematol, 21, pp.129~138 (2008)
20. Fuste B, "Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK", Haematologica, 89, pp.578~585 (2004)
21. Mercanoglu F, "Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels", Transplant Proc, 36, pp.1357~1360 (2004)
22. Salat C, "Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation", Blood, 89, pp.2184~2188 (1997)
23. Cutler C, "Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation", Blood, 112, pp.4425~4431 (2008)
24. Khimani F, "Hepatic veno-occlusive disease following sirolimus-based immune suppression", Bone Marrow Transplant, 54, pp.85~89 (2019)
25. Wadleigh M, "Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation", Blood, 102, pp.1578~1582 (2003)
26. Mohty M, "Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome", veno-occlusive disease in adult patients : a position statement from an international expert group, 2020, pp.55, 485~495
27. Carreras E, "Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party", Blood, 92, pp.3599~3604 (1998)
28. Nagler A, "Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome", Bone Marrow Transplant, 49, pp.628~633 (2014)
29. Yoon JH, "Incidence and risk factors of hepatic veno-occlusive disease", sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1, 2021, pp.56, 1603~1613
30. Lee SC, "Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin’s lymphoma", Bone Marrow Transplant, 45, pp.801~802 (2010)
31. Lee JL, "Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy : incidence, risk factors, and outcome", Biol Blood Marrow Transplant, 5, pp.306~315 (1999)
32. Yakushijin K, "Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation : incidence, risk factors and outcomes", Bone Marrow Transplant, 51, pp.403~409 (2016)
33. 김인호, "Allogeneic Stem Cell Transplantation for Patients with Advanced Hematological Malignancies: Comparison of Fludarabine-based Reduced Intensity Conditioning versus Myeloablative Conditioning", Journal of Korean Medical Science, 22(2), pp.227~234 (2007), 대한의학회
34. Tsirigotis PD, "Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen", Bone Marrow Transplant, 49, pp.1389~1392 (2014)
35. Lee JH, "Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation", Ann Hematol, 84, pp.321~330 (2005)
36. Hwang DY, "High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma", Leuk Lymphoma, 57, pp.51~57 (2016)
37. Kim KH, "Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma : a multicenter study from the consortium for improving survival of lymphoma", Transpl Int, 33, pp.1211~1219 (2020)
38. Yoon JH, "Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas", Bone Marrow Transplant, 54, pp.330~333 (2019)
39. Song GY, "Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma : a propensity scorematched analysis", Leuk Lymphoma, 61, pp.2714~2721 (2020)
40. Jung SH, "Phase 2 study of an intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma(KMM150)", Biol Blood Marrow Transplant, 24, pp.923~929 (2018)
41. Ramasamy K, "Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning(RIC)haematopoietic stem cell transplantation(HSCT)", Bone Marrow Transplant, 38, pp.823~824 (2006)
42. Lewis C, "Incidence, predictors, and outcomes of veno-occlusive disease", sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation, 2020, pp.26, 529~539
43. Hagglund H, "Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation", Blood, 92, pp.4568~4572 (1998)
44. Armand P, "Validation and refinement of the disease risk index for allogeneic stem cell transplantation", Blood, 123, pp.3664~3671 (2014)
45. Cesaro S, "A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation", Haematologica, 90, pp.1396~1404 (2005)
46. Corbacioglu S, "Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide", Bone Marrow Transplant, 38, pp.547~553 (2006)
47. Cheuk DK, "Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation", Bone Marrow Transplant, 40, pp.935~944 (2007)
48. Xia Y, "Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients : incidence and associated risk factors, a meta-analysis", Eur J Gastroenterol Hepatol, 33, pp.872~884 (2021)
49. Je-Hwan Lee, "Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation", Blood Research, 50(3), pp.123~125 (2015), 대한혈액학회
50. Mi Young Yeom, "Hepatic veno-occlusive disease may develop in secondary iron overloaded mice after allogeneic hematopoietic stem cell transplantation with total body irradiation", Blood Research, 50(3), pp.140~146 (2015), 대한혈액학회
51. Yoon JH, "HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis", Ther Adv Hematol, 11, pp.2040620720936935~ (2020)
52. Lee SH, "Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation : incidence, risk factors, and outcome", Bone Marrow Transplant, 45, pp.1287~1293 (2010)
53. Corbacioglu S, "Risk factors for development of and progression of hepatic veno-occlusive disease", sinusoidal obstruction syndrome, 2019, pp.25, 1271~1280
54. Kernan NA, "Defibrotide for the treatment of hepatic veno-occlusive disease", sinusoidal obstruction syndrome following nontransplant-associated chemotherapy : final results from a post hoc analysis of data from an expanded-access program, 2018, pp.65, e27269~
55. Carmona A, "Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells : protective effect of defibrotide", Biol Blood Marrow Transplant, 19, pp.1439~1445 (2013)
56. Seo AN, "Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy", Clin Mol Hepatol, 20, pp.81~84 (2014)
57. Choi JH, "Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver", Oncol Lett, 11, pp.2861~2864 (2016)
58. Han NY, "Hepatic parenchymal heterogeneity as a marker for oxaliplatin-induced sinusoidal obstruction syndrome : correlation with treatment response of colorectal cancer liver metastases", AJR Am J Roentgenol, 209, pp.1039~1045 (2017)
59. Castaigne S, "Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia(ALFA-0701) : a randomised, open-label, phase 3 study", Lancet, 379, pp.1508~1516 (2012)
60. Magwood-Golston JS, "Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome : findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry", Leuk Res, 44, pp.61~64 (2016)
61. Amadori S, "Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy : results of the randomized phase III EORTC-GIMEMA AML-19 trial", J Clin Oncol, 34, pp.972~979 (2016)
62. Battipaglia G, "Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment : a retrospective study from the Acute Leukemia Working Party of the EBMT", Bone Marrow Transplant, 52, pp.592~599 (2017)
63. Kantarjian HM, "Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia : final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study", Cancer, 125, pp.2474~2487 (2019)
64. Kebriaei P, "Management of important adverse events associated with inotuzumab ozogamicin : expert panel review", Bone Marrow Transplant, 53, pp.449~456 (2018)
65. Kim DS, "Introduction : health of the health care system in Korea", Soc Work Public Health, 25, pp.127~141 (2010)
66. Corbacioglu S, "Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation : an open-label, phase 3, randomised controlled trial", Lancet, 379, pp.1301~1309 (2012)
67. Carreras E, "Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients", Biol Blood Marrow Transplant, 13, pp.1448~1454 (2007)
68. Carreras E, "How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation", Br J Haematol, 168, pp.481~491 (2015)
69. Mehra V, "Early and late-onset veno-occlusive disease", sinusoidal syndrome post allogeneic stem cell transplantation : a real-world UK experience, 2021, pp.21, 864~869
70. Corbacioglu S, "Incidence of anicteric veno-occlusive disease", sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients, 2020, pp.26, 1342~1349
71. Cairo MS, "Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS", VOD after haematopoietic cell transplantation, 2020, pp.190, 822~836
72. 신승환, "Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation", Blood Research, 48(1), pp.55~57 (2013), 대한혈액학회
73. Roeker LE, "Early clinical predictors of hepatic veno-occlusive disease", sinusoidal obstruction syndrome after myeloablative stem cell transplantation, 2019, pp.25, 137~144
74. Lee JH, "Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide", Br J Haematol, 118, pp.1087~1094 (2002)
75. Lee JH, "Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia", Bone Marrow Transplant, 26, pp.657~662 (2000)
76. Scrobohaci ML, "Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers", Thromb Res, 63, pp.509~519 (1991)
77. Collins PW, "von Willebrand factor as a marker of endothelial cell activation following BMT", Bone Marrow Transplant, 10, pp.499~506 (1992)
78. Akil A, "Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation", Biol Blood Marrow Transplant, 21, pp.1739~1745 (2015)
79. Lee JH, "Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation : a prospective study", Bone Marrow Transplant, 22, pp.883~888 (1998)
80. Iguchi A, "Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease(VOD)in stem cell transplantation", Pediatr Blood Cancer, 54, pp.437~443 (2010)
81. Piao Z, "Effect of FOXP3 polymorphism on the clinical outcomes after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia patients", Int Immunopharmacol, 31, pp.132~139 (2016)
82. Strouse C, "Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant", Biol Blood Marrow Transplant, 24, pp.2072~2080 (2018)
83. Jiang S, "Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel", Haematologica, 106, pp.446~453 (2021)
84. Song GY, "Endothelial activation and stress index(EASIX)is a reliable predictor for overall survival in patients with multiple myeloma", BMC Cancer, 20, pp.803~ (2020)
85. Varma A, "Endothelial Activation and Stress Index(EASIX)at admission predicts fluid overload in recipients of allogeneic stem cell transplantation", Biol Blood Marrow Transplant, 26, pp.1013~1020 (2020)
86. Luft T, "EASIX and mortality after allogeneic stem cell transplantation", Bone Marrow Transplant, 55, pp.553~561 (2020)
87. Shouval R, "External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation", Blood Adv, 3, pp.1881~1890 (2019)
88. Luft T, "EASIX in patients with acute graft-versus-host disease : a retrospective cohort analysis", Lancet Haematol, 4, pp.e414~e423 (2017)
89. Park JE, "Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation", Eur Radiol, 28, pp.2291~2298 (2018)
90. Chung H, "Ultrasound in hepatic veno-occlusive disease(HVOD)after pediatric hematopoietic stem cell transplantation(HSCT) : comparison of diagnostic criteria including the pediatric criteria of european society for blood and marrow transplantation(EBMT)", Pediatr Hematol Oncol, 37, pp.275~287 (2020)
91. Hong EK, "Assessment of hepatic sinusoidal obstruction syndrome with intravoxel incoherent motion diffusion-weighted imaging : an experimental study in a rat model", J Magn Reson Imaging, 51, pp.81~89 (2020)
92. Shin J, "Liver stiffness and perfusion changes for hepatic sinusoidal obstruction syndrome in rabbit model", World J Gastroenterol, 26, pp.706~716 (2020)
93. Park SH, "Noninvasive assessment of hepatic sinusoidal obstructive syndrome using acoustic radiation force impulse elastography imaging : a proofof-concept study in rat models", Eur Radiol, 28, pp.2096~2106 (2018)
94. Richardson PG, "The use of defibrotide in blood and marrow transplantation", Blood Adv, 2, pp.1495~1509 (2018)
95. Richardson PG, "Defibrotide sodium for the treatment of hepatic veno-occlusive disease", sinusoidal obstruction syndrome, 2018, pp.11, 113~124
96. Richardson PG, "Earlier defibrotide initiation post-diagnosis of veno-occlusive disease", sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation, 2017, pp.178, 112~118
97. Richardson PG, "Defibrotide for patients with hepatic veno-occlusive disease", sinusoidal obstruction syndrome : interim results from a treatment IND study, 2017, pp.23, 997~1004
98. Ho VT, "Hepatic veno-occlusive disease after hematopoietic stem cell transplantation : update on defibrotide and other current investigational therapies", Bone Marrow Transplant, 41, pp.229~237 (2008)
99. Yoon JH, "Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?", Bone Marrow Transplant, 48, pp.1562~1568 (2013)
100. Hennenfent KL, "Is there a role for high-dose methylprednisolone in the treatment of hepatic regimen-related toxicity?", Bone Marrow Transplant, 37, pp.229~ (2006)
101. Al Beihany A, "Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone", Bone Marrow Transplant, 41, pp.287~291 (2008)
102. Khoury H, "Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?", Bone Marrow Transplant, 25, pp.737~743 (2000)
103. Haussmann U, "Hepatic veno-occlusive disease in pediatric stem cell transplantation : impact of pre-emptive antithrombin III replacement and combined antithrombin III", defibrotide therapy, 2006, pp.91, 795~800
104. Gomez-Centurion I, "Transjugular intrahepatic portosystemic shunt for very severe veno-occlusive disease", sinusoidal obstruction syndrome(VOD, Biol Blood Marrow Transplant, pp.2020, 26[DOI]
105. Azoulay D, "Transjugular intrahepatic portosystemic shunt(TIPS)for severe veno-occlusive disease of the liver following bone marrow transplantation", Bone Marrow Transplant, 25, pp.987~992 (2000)
106. Kim ID, "A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation", Am J Transplant, 2, pp.796~800 (2002)
107. Wadleigh M, "Hepatic veno-occlusive disease : pathogenesis, diagnosis and treatment", Curr Opin Hematol, 10, pp.451~462 (2003)
108. Chao N, "How I treat sinusoidal obstruction syndrome", Blood, 123, pp.4023~4026 (2014)
109. Kernan NA, "Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease", sinusoidal obstruction syndrome, 2018, pp.181, 816~827
110. Essell JH, "Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial", Ann Intern Med, 128(12 Pt 1), pp.975~981 (1998)
111. Ruutu T, "Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation", Blood, 100, pp.1977~1983 (2002)
112. Ohashi K, "The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation", Am J Hematol, 64, pp.32~38 (2000)
113. Tay J, "Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation", Biol Blood Marrow Transplant, 13, pp.206~217 (2007)
114. Park SH, "A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation", Bone Marrow Transplant, 29, pp.137~143 (2002)
115. Marsa-Vila L, "Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation", Eur J Haematol, 47, pp.346~354 (1991)
116. Attal M, "Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin : a prospective, randomized trial", Blood, 79, pp.2834~2840 (1992)
117. Or R, "Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients", Transplantation, 61, pp.1067~1071 (1996)
118. Imran H, "Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation : a systematic review and meta-analysis", Bone Marrow Transplant, 37, pp.677~686 (2006)
119. Gluckman E, "Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation", Br J Haematol, 74, pp.277~281 (1990)
120. Bearman SI, "A phase I", II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation, 1993, pp.84, 724~730
121. 송준섭, "Prophylactic Low-dose Heparin or Prostaglandin E(1) may Prevent Severe Veno-occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation in Korean Children", Journal of Korean Medical Science, 21(5), pp.897~903 (2006), 대한의학회
122. Park M, "Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation", Ann Transplant, 18, pp.36~42 (2013)

관련 논문AI추천